Spots Global Cancer Trial Database for checkpoint inhibition
Every month we try and update this database with for checkpoint inhibition cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade | NCT03493932 | Glioblastoma | Nivolumab BMS-986016 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Improve Checkpoint-blockade Response in Advanced Urothelial Cancer | NCT03871036 | Urothelial Carc... | Tremelimumab Durvalumab Paclitaxel | 18 Years - | The Netherlands Cancer Institute | |
| A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer | NCT03499899 | Triple-negative... | LAG525 PDR001 Carboplatin | 18 Years - | Novartis | |
| A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer | NCT03499899 | Triple-negative... | LAG525 PDR001 Carboplatin | 18 Years - | Novartis | |
| Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer | NCT05148546 | Renal Cell Carc... | Neoadjuvant niv... Neoadjuvant ipi... Neoadjuvant rel... | 18 Years - | The Netherlands Cancer Institute | |
| Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer | NCT03168139 | Metastatic Colo... Metastatic Panc... | Olaptesed pegol... Olaptesed pegol... | 18 Years - | TME Pharma AG | |
| Improve Checkpoint-blockade Response in Advanced Urothelial Cancer | NCT03871036 | Urothelial Carc... | Tremelimumab Durvalumab Paclitaxel | 18 Years - | The Netherlands Cancer Institute | |
| Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma | NCT04949113 | Malignant Melan... | Neoadjuvant ipi... Adjuvant nivolu... | 16 Years - | The Netherlands Cancer Institute | |
| LIFE - Lung Cancer, Immunotherapy, Frailty, Effect | NCT03870464 | Non-small Cell ... Quality of Life Brain Metastase... Venous Thromboe... | CT-scans extend... MRI scan of the... Prospective reg... Quality of Life... | 18 Years - | University of Southern Denmark | |
| Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma | NCT03473756 | Urothelial Carc... | Rogaratinib (BA... Atezolizumab | 18 Years - | Bayer | |
| Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer | NCT03168139 | Metastatic Colo... Metastatic Panc... | Olaptesed pegol... Olaptesed pegol... | 18 Years - | TME Pharma AG | |
| A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) | NCT03729245 | Renal Cell Carc... Metastatic Rena... | bempegaldesleuk... sunitinib nivolumab cabozantinib | 18 Years - | Nektar Therapeutics | |
| Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL | NCT03212807 | EBV Related Non... Primary CNS Lym... Primary Testicu... | Durvalumab Lenalidomide | 21 Years - 80 Years | Singapore General Hospital | |
| Neoadjuvant Triple Treatment for Borderline Resectable Pancreatic Cancer (PREOPANC-5) | NCT06384560 | Borderline Rese... | Pembrolizumab | 18 Years - | Amsterdam UMC, location VUmc | |
| Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer | NCT05148546 | Renal Cell Carc... | Neoadjuvant niv... Neoadjuvant ipi... Neoadjuvant rel... | 18 Years - | The Netherlands Cancer Institute | |
| Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma | NCT04949113 | Malignant Melan... | Neoadjuvant ipi... Adjuvant nivolu... | 16 Years - | The Netherlands Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
